Page last updated: 2024-09-03

gefitinib and Laryngeal Neoplasms

gefitinib has been researched along with Laryngeal Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Bostrom, B; Drehner, D; Lander, T; Marker, S; Sidman, J	1

Other Studies

2 other study(ies) available for gefitinib and Laryngeal Neoplasms

Article	Year
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
Gefitinib therapy for life-threatening laryngeal papillomatosis. Archives of otolaryngology--head & neck surgery, 2005, Volume: 131, Issue:1 Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome	2005

Article

Year

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins

2004

Gefitinib therapy for life-threatening laryngeal papillomatosis.

Archives of otolaryngology--head & neck surgery, 2005, Volume: 131, Issue:1

Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome

2005